Atlas Capital Advisors Inc. Buys 2,412 Shares of Fresenius Medical Care AG (NYSE:FMS)

Atlas Capital Advisors Inc. boosted its stake in shares of Fresenius Medical Care AG (NYSE:FMS) by 14.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 18,688 shares of the company’s stock after acquiring an additional 2,412 shares during the period. Atlas Capital Advisors Inc.’s holdings in Fresenius Medical Care were worth $423,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Fresenius Medical Care by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock worth $28,000 after purchasing an additional 806 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Fresenius Medical Care in the 3rd quarter valued at about $38,000. Jones Financial Companies Lllp raised its position in shares of Fresenius Medical Care by 80.5% in the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after buying an additional 2,012 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Fresenius Medical Care by 8.4% during the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock worth $129,000 after acquiring an additional 441 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Fresenius Medical Care by 43.3% during the 4th quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock worth $162,000 after acquiring an additional 2,166 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on FMS. StockNews.com upgraded shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Truist Financial boosted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Price Performance

FMS stock opened at $23.94 on Friday. The stock has a market cap of $14.05 billion, a price-to-earnings ratio of 19.79, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The company has a 50 day simple moving average of $24.14 and a 200 day simple moving average of $22.65. Fresenius Medical Care AG has a 1 year low of $17.93 and a 1 year high of $25.96.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.